These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1697 related articles for article (PubMed ID: 8597337)

  • 1. [Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a].
    Corbillet V; Celerier P; Lebon P; Litoux P; Dreno B
    Ann Med Interne (Paris); 1995; 146(6):399-403. PubMed ID: 8597337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adjuvant therapy with recombinant interferon alfa-2a in metastasized malignant melanoma].
    Elsässer-Beile U; Garbe C; Stadler R; Drews H; Schöpf E
    Hautarzt; 1989 May; 40(5):266-70. PubMed ID: 2737901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
    Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
    Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exacerbation of psoriasis during alpha-interferon therapy].
    Hartmann F; von Wussow P; Deicher H
    Dtsch Med Wochenschr; 1989 Jan; 114(3):96-8. PubMed ID: 2912680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
    Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
    Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
    Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
    J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion.
    Ludwig CU; Ludwig-Hagemann R; Obrist R; Obrecht JP; Holdener EE; Sutter-Melde C
    Onkologie; 1990 Apr; 13(2):117-22. PubMed ID: 2197582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More on cutaneous reactions to recombinant cytokine therapy.
    Le Gal FA; Paul C; Chemaly P; Dubertret L
    J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
    [No Abstract]   [Full Text] [Related]  

  • 12. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
    Johnson DM; Hayat SQ; Burton GV
    J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma.
    Dummer R; Hauschild A; Henseler T; Burg G
    Lancet; 1998 Sep; 352(9131):908-9. PubMed ID: 9743016
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
    Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
    Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
    Hanson DS; Leggette CT
    Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma.
    Sertoli MR; Bernengo MG; Ardizzoni A; Brunetti I; Falcone A; Vidili MG; Cusimano MP; Appino A; Doveil G; Fortini C
    Oncology; 1989; 46(2):96-8. PubMed ID: 2710482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
    Prümmer O
    Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.